By inhibiting the negative regulator of skeletal muscle mass, myostatin (also known as GDF-8), myostatin inhibitors could be used to significantly increase skeletal muscle mass and attenuate disease severity in DMD. This evidence concerns the gene MSTN and Duchenne muscular dystrophy.